CAS Number: 51-43-4
Used as a systemic drug for cardiac resuscitation and locally in topical anesthetic preparations, epidural anesthesia, eye drops (mydriatic), and nasal drops (vasoconstrictor). At last update no published data on excretion in breast milk were found.Its rapid metabolism (short Tmax and T½) makes it unlikely an excretion into milk in significant amounts. It is destroyed in the gastrointestinal tract. The low oral-bioavailability makes its levels into infant's plasma, that would be absorbed from ingested breast milk, be nil or negligible. Maintained high intravenous doses decrease milk production by interfering with the secretion of prolactin especially the early postpartum-weeks, because when breastfeeding is well established, prolactin levels do not correlate with milk production any longer. No problems related to lactation have been observed due to epidural anesthesia in which adrenaline is used.
At latest update, relevant published data on excretion into breast milk were not found. It contains triterpenic saponins (asiaticoside and madecassoside), tannins, phytosterols and essential oil. Frequent and exaggerated use of triterpenes may cause liver damage. Properties that are attributed for topical use (some clinically tested) like are healing of wound and venous tonic. There is no proof on effectiveness when used by mouth. Because of a low or nil systemic absorption through skin or vaginal mucosa, the topical use is believed be compatible with breastfeeding. Do not use it on the breast or clean it thoroughly to avoid ingestion by the infant. Avoid oral administration.
CAS Number: 77-92-9
Product that is naturally found in most fruits, especially citrus ones, and which is industrially produced through fermentation of sugar by the fungus Aspergillus niger. It is used in medical compounds as effervescent, to treat intestinal affections, as antioxidant, as an agent for alkalizing urine and dissolution of urinary tract stones. In the food industry it is used as additive (E 330) due to its antioxidant, preservative and flavoring properties. Devoid of toxicity when used at appropriate doses.
CAS Number: 64-86-8
It is used for treatment of Gout, Familial Mediterranean Fever. As well as for other conditions like Amyloidosis, Behçet's Syndrome, Pericarditis, Primary Biliary Cirrhosis and Pyoderma gangrenosum. It is excreted in breast milk in quantities that differ according to different published studies, from no clinically significant in some, until being important in others, but there have been no problems in infants whose mothers were treated, even after months, with undetectable plasma levels in these infants. The concomitant use of macrolide antibiotics and fruit juices (both the mother and the infant) , especially grape-fruit, is not recommended since they may interfere with bile excretion and greatly increase toxicity. The American Academy of Breastfeeding rates it as compatible with breastfeeding. List of Essential Medicines of WHO (2002): compatible with breastfeeding
CAS Number: 110-17-8
Anti-inflammatory and immunomodulator used in the treatment of psoriasis and in relapsing forms of multiple sclerosis. Since the last update we have not found published data on its excretion in breast milk. Its pharmacokinetic data (large volume of distribution and short half-life) make it unlikely that milk would pass through in significant quantities (Almas 2016).Possible side effects are rare and generally not serious, with no immunosuppressive effects or higher frequency of infections (EMA 2017, AEMPS 2015). Until there is more published data on this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in case of prematurity (Brown 2017, Yiu 2015, Bove 2014, Cree 2013).
CAS Number: 406-76-8
Amino acid that is present in many foods, among them the milk. Indication is the treatment of Primary Deficiency of Carnitine, or, Secondary Deficiency due to Hemolysis, Myocardiopathy and other diseases. Only Levocarnitine is effective as a supplement, with the consumption of D-carnitine regarded as a risk for deficiency. Normal levels in the milk are not modified by the consumption of supplements of Carnitine. Mean concentration level within the first month is about 10 to 12 mg/L, with lower levels in the next following months. The supplementation with Carnitine of the milk for premature infants does not improve their weight increment, with no proof of a beneficial effect.
CAS Number: 50-21-5
A natural product found in milk that may increase their concentration after exercise which is not harmful to the infant. At latest update published were not found data on excretion in breast milk.Because the small dose used and poor absorption to the plasma of most topical dermatological or vaginal preparations, make it unlikely the pass of a significant amount into breast milk. Do not apply on the nipple or areola.
CAS Number: 9001-62-1
Proteolytic and lipolytic enzyme which is derived from mammalian pancreas that has protease, lipase and amylase activity. Indicated for treatment of cystic fibrosis and chronic pancreatitis. At latest update no published data on excretion into breast milk was found. Its high molecular weight and poor intestinal absorption make it highly unlikely a significant passage to the milk.A low oral bioavailability hinders the passage into infant plasma from ingested milk. It is a medication used in children and young infants.
CAS Number: 123-31-9
Benzene derivative which is topically used with creams and solutions (2-4%) as a bleaching agent for several skin disorders associated to hyper-pigmentation. In industry it is used as photographic developer. TLV or threshold limit value which means maximum exposure limit for workers is 2 mg / m3 (Flickinger 1976). At latest update relevant published data were not found on excretion into breast milk. It is well absorbed through the skin, both when used as a therapeutic agent (Bucks 1998, Wester 1998, Westerhof 2005, Andersen 2010, Bozzo 2011) or industrial use (Barber 1995, McGregor 2007), however, a significant excretion into breastmilk is not likely for their lack of fat solubility. There is controversy and doubt about a possible mutagenic and carcinogenic effect (Kooyers 2004, FDA 2006, Levitt 2007, Andersen 2010), so it does not seem wise a chronic or continued use while breastfeeding. Do not apply it on the breast to prevent ingestion by the infant; otherwise, do it just after a meal and clean the nipple thoroughly with water before the next feed.Do not apply it over large areas or on long-term treatments to avoid an excessive systemic absorption.
CAS Number: 141-01-5
Several ferrous salts of iron (ascorbate, aspartate, citrate, chloride, fumarate, gluconate, lactate, oxalate, succinate, sulfate, glycine sulfate, etc.) are used in oral administration for treating or preventing iron deficiency anemia.Its molecular weight varies from 170 for the fumarate and succinate, and from 280 for lactate and sulfate to 400 for aspartate and ascorbate. Characteristics of iron metabolism in the body make unlikely that it would be excreted in a significant amount into breast milk.It is a medication used for treatment of Neonatal Anemia in premature babies. Iron is excreted in small amounts in human milk, usually being enough for covering the daily needs of infants due to its high bioavailability. There is no correlation between mother's daily intake of iron and its concentration in breast milk.Iron supplementation to the mother does not increase levels of iron in breast milk or infant plasma significantly. Excessive supplementation can reduce the zinc concentration in milk. WHO List of Essential Medicines 2002: compatible with breastfeeding.
CAS Number: 7447-40-7
Human milk has a potassium concentration of 13 meq/L, almost a half of rehydration solution content and a quarter of maximal IV recommended dose. Potassium supplementation does not alter milk concentration without increasing mother’s serum concentration, which is strictly limited from 3,5 to 5,5 meq/L.
CAS Number: 51-43-4
No information is available on the use of epinephrine during breastfeeding. Because of its poor oral bioavailability and short half-life, any epinephrine in milk is unlikely to affect the infant. High intravenous doses of epinephrine might reduce milk production or milk letdown. Low-dose intramuscular (such as Epi-Pen), epidural, topical, inhaled or ophthalmic epinephrine are unlikely to interfere with breastfeeding. To substantially diminish the effect of the drug after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue.
CAS Number: 64-86-8
Long-term prophylactic maternal doses of colchicine up to 1.5 mg daily produce levels in milk that result in the infant receiving less than 10% of the maternal weight-adjusted dosage. The highest milk levels occur 2 to 4 hours after a dose, so avoiding breastfeeding during this time can minimize the infant dose, although some clinicians simply recommend taking the drug after nursing. No adverse effects in breastfed infants have been reported in case series and a case-control study and some authors consider colchicine safe during breastfeeding in women being treated for familial Mediterranean fever or rheumatic conditions.[1][2][3][4]
CAS Number: 541-15-1; 3040-38-8;
Levocarnitine and acetyl-l-carnitine (acetlycarnitine) are normal components of human milk that are required for fat metabolism. The body can use only levocarnitine, and dextrocarnitine can be an antagonist of levocarnitine. Acetyl-l-carnitine, and propionyl-l-carnitine can be converted to levocarnitine by the body. The bioavailability of levocarnitine is less than 20%, but acetylcarnitine and propionlycarnitine may be higher. These substances have no specific lactation-related uses. Within the normal range of dietary intake, excretion of levocarnitine into breastmilk is relatively constant. Women with carnitine deficiency appear to secrete insufficient amounts of carnitine into their breastmilk for their breastfed infants, who may require levocarnitine supplementation.[1] Preterm infants are often deficient in levocarnitine and require supplementation.[2] No data exist on the safety and efficacy levocarnitine supplementation in nursing mothers or infants without carnitine deficiency. Levocarnitine and its derivatives are generally well tolerated in adults with occasional gastrointestinal upset and restlessness. A fishy odor to the breath, sweat and urine has been reported. Although data are very limited, poor bioavailability might limit absorption by the breastfed infant. It appears unlikely that maternal levocarnitine supplements during nursing would be harmful to the infant, but until more data are available, it is probably best to avoid levocarnitine supplementation unless it is prescribed by a healthcare professional. Pasteurization (method not stated) had little effect on the concentration of endogenous carnitine in one study. Pasteurization followed by refrigeration at 5 degrees C for 48 hours reduced the carnitine concentration by about 13%.[3]
CAS Number: 123-31-9
Topical hydroquinone has not been studied during breastfeeding. Hydroquinone is not contraindicated during breastfeeding and if hydroquinone is required by the mother, it is not a reason to discontinue breastfeeding. However, some experts feel that long-term use of hydroquinone is difficult to justify in a nursing mother.[1] If hydroquinone is used, ensure that the infant's skin does not come into direct contact with the areas of maternal skin that have been treated and the infant does not ingest the product from the mother's skin.
If consumed moderately liver and various organ meats are compatible in breast feeding.
If consumed moderately liver and various organ meats are compatible in breast feeding.
Not much study has been done on safety of Viatrexx-adipose in breastfeeding and its ingredients. Even we do not have complete information about usage of Viatrexx-adipose in breastfeeding so at this point a trained medical professional could be your best bet. If you observe anything abnormal with your baby please contact 911.
If your doctor considers Viatrexx-adipose safe enough to prescribe for you that means its benefits should outweigh its known risks for you.
We are not Sure, Please check with your healthcare provider or doctor.
US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday
UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700
Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week
Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week